Pharmaceutical News and Articles

Weight-Loss Pill Saxenda Helps Kids as Young as 6

but when used alone, the effect is modest and, as yet, no medication is approved for the treatment of general obesity in children who are younger than 12. Lirag

FDA to Investigate Safety of Toxic Metals in Tampons

The U.S. Food and Drug Administration announced Tuesday that it will launch an independent review into any possible effects of toxic metals found in tampons.The

Dupixent Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria

TARRYTOWN, N.Y. and PARIS, Sept. 11, 2024. Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Dupixent (dupilumab) confirmatory Phase 3 trial (LI

First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA in mIDH1 AML

SOUTH SAN FRANCISCO, Calif., Sept. 5, 2024. Rigel Pharmaceuticals, a commercial stage biotechnology company focused on hematologic disorders and cancer, today a

Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

BASKING RIDGE, N.J. RAHWAY, N.J., September 7, 2024 Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01 phase 2 trial sh

Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan Was Predictive of Clinical Outcomes in Patients With Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial

Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca s proprietary computational pathology platfor

First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma

HOUSTON, Sept. 9, 2024. Moleculin Biotech, Inc., ( Moleculin or the Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio of drug can

Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes

INDIANAPOLIS, Sept. 10, 2024. Eli Lilly and Company today announced detailed results from the QWINT-2 phase 3 trial evaluating once-weekly insulin efsitora alfa

Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

Apple Will Sell Air Pods With Hearing Aids Built In

The latest AirPods from Apple will come with built-in hearing aids, the company announced Monday. Designed as an over-the-counter hearing aid feature for those